Abstract
Cell culture, tissue chemistry and flow cytometry were used to determine whether antisense c-Met oligodeoxynucleotides enhanced the sensitivity of human glioma cells to paclitaxel. A combination of paclitaxel with antisense c-Met oligodeoxynucleotides inhibited cell growth, induced apoptosis and induced c-Met protein expression in U251 and SHG44 human glioma cells more significantly than either paclitaxel or the oligodeoxynucleotides on their own (P<0.01). Thus, c-Met antisense oligodeoxynucleotides increase the sensitivity of human glioma cells to paclitaxel. Combined use of the two agents could be a novel and attractive strategy in human glioma treatment.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Apoptosis / drug effects
-
Apoptosis / genetics
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / genetics
-
Brain Neoplasms / metabolism
-
Brain Neoplasms / pathology
-
Caspase 3 / metabolism
-
Cell Proliferation / drug effects
-
Drug Evaluation, Preclinical
-
Drug Resistance, Neoplasm / drug effects*
-
Drug Synergism
-
Gene Expression Regulation, Neoplastic / drug effects
-
Glioma / drug therapy*
-
Glioma / genetics
-
Glioma / metabolism
-
Glioma / pathology
-
Humans
-
Oligodeoxyribonucleotides, Antisense / administration & dosage
-
Oligodeoxyribonucleotides, Antisense / pharmacology*
-
Paclitaxel / administration & dosage*
-
Proto-Oncogene Proteins c-met / antagonists & inhibitors*
-
Proto-Oncogene Proteins c-met / genetics
-
Proto-Oncogene Proteins c-met / metabolism
-
Tumor Cells, Cultured
Substances
-
Oligodeoxyribonucleotides, Antisense
-
Proto-Oncogene Proteins c-met
-
Caspase 3
-
Paclitaxel